Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab
Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2‐year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post‐transplant +22nd mont...
Gespeichert in:
| Veröffentlicht in: | Pediatric blood & cancer 2014-05, Vol.61 (5), p.928-930 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 930 |
|---|---|
| container_issue | 5 |
| container_start_page | 928 |
| container_title | Pediatric blood & cancer |
| container_volume | 61 |
| creator | Unal, Sule Sag, Erdal Kuskonmaz, Baris Kesici, Selman Bayrakci, Benan Ayvaz, Deniz C. Tezcan, Ilhan Yalnızoglu, Dilek Uckan, Duygu |
| description | Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2‐year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post‐transplant +22nd month and required respiratory support with mechanical ventilation. She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance. She is currently asymptomatic on the 6th month of follow‐up. Pediatr Blood Cancer 2014;61:928–930. © 2013 Wiley Periodicals, Inc. |
| doi_str_mv | 10.1002/pbc.24799 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1506398397</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1506398397</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3919-7c49df74e66eb68ff5d9b5e35bfc91d6144fdd3faca0647bd5eb0cc489189da03</originalsourceid><addsrcrecordid>eNp1kc9uEzEQh1cIRP_AgRdAlrjAIa0d27vrI0QQQFUBAerR8trjxGXXXmxvm7xInxeHtDkgcbJH_ubTjH9V9YLgM4Lx_Hzs9NmcNUI8qo4JZ3zGMWkeH-5YHFUnKV0XtMa8fVodzRnFTV3j4-ru-6Q1pGSnHuUIKg_gMwoWJbiBCGjYqpTX4J1Cq6huXEKmPPRhBIOUzRCR6vuwAg9OozUMKocxOMilShkGpKHfiZVPY698VtkFj25dXqNSp0Eh2Oi18itAyhsUXZ42blDds-qJVX2C5_fnafXzw_sfi4-ziy_LT4u3FzNNBRGzRjNhbMOgrqGrW2u5ER0HyjurBTE1YcwaQ63SCtes6QyHDmvNWkFaYRSmp9XrvXeM4fcEKcvBpd3MykOYkiQc11S0VDQFffUPeh2m6Mt0O4rjFgvKCvVmT-kYUopg5RjLQnErCZa7sGQJS_4Nq7Av741TN4A5kA_pFOB8D9y6Hrb_N8mv7xYPytm-w5Xf3xw6VPwl64Y2XF5dLuXV50uy_MZaKegfp3Sxyg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1505080934</pqid></control><display><type>article</type><title>Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Unal, Sule ; Sag, Erdal ; Kuskonmaz, Baris ; Kesici, Selman ; Bayrakci, Benan ; Ayvaz, Deniz C. ; Tezcan, Ilhan ; Yalnızoglu, Dilek ; Uckan, Duygu</creator><creatorcontrib>Unal, Sule ; Sag, Erdal ; Kuskonmaz, Baris ; Kesici, Selman ; Bayrakci, Benan ; Ayvaz, Deniz C. ; Tezcan, Ilhan ; Yalnızoglu, Dilek ; Uckan, Duygu</creatorcontrib><description>Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2‐year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post‐transplant +22nd month and required respiratory support with mechanical ventilation. She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance. She is currently asymptomatic on the 6th month of follow‐up. Pediatr Blood Cancer 2014;61:928–930. © 2013 Wiley Periodicals, Inc.</description><identifier>ISSN: 1545-5009</identifier><identifier>EISSN: 1545-5017</identifier><identifier>DOI: 10.1002/pbc.24799</identifier><identifier>PMID: 24307660</identifier><language>eng</language><publisher>United States: Blackwell Publishing Ltd</publisher><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use ; Antineoplastic Agents - therapeutic use ; bone marrow transplantation ; Combined Modality Therapy ; Cyclosporine - therapeutic use ; Female ; Graft vs Host Disease - etiology ; Graft vs Host Disease - therapy ; graft-versus-host disease ; Griscelli syndrome ; Hearing Loss, Sensorineural - complications ; Hearing Loss, Sensorineural - therapy ; Hematology ; Hematopoietic Stem Cell Transplantation - adverse effects ; Humans ; Immunosuppressive Agents - therapeutic use ; Infant ; myasthenia gravis ; Myasthenia Gravis - diagnosis ; Myasthenia Gravis - etiology ; Myasthenia Gravis - therapy ; Mycophenolic Acid - analogs & derivatives ; Mycophenolic Acid - therapeutic use ; Oncology ; Pediatrics ; Piebaldism - complications ; Piebaldism - therapy ; Pigmentation Disorders - complications ; Pigmentation Disorders - therapy ; Plasma Exchange ; Remission Induction ; Rituximab ; Transplantation, Homologous ; Treatment Outcome</subject><ispartof>Pediatric blood & cancer, 2014-05, Vol.61 (5), p.928-930</ispartof><rights>2013 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3919-7c49df74e66eb68ff5d9b5e35bfc91d6144fdd3faca0647bd5eb0cc489189da03</citedby><cites>FETCH-LOGICAL-c3919-7c49df74e66eb68ff5d9b5e35bfc91d6144fdd3faca0647bd5eb0cc489189da03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fpbc.24799$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fpbc.24799$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24307660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Unal, Sule</creatorcontrib><creatorcontrib>Sag, Erdal</creatorcontrib><creatorcontrib>Kuskonmaz, Baris</creatorcontrib><creatorcontrib>Kesici, Selman</creatorcontrib><creatorcontrib>Bayrakci, Benan</creatorcontrib><creatorcontrib>Ayvaz, Deniz C.</creatorcontrib><creatorcontrib>Tezcan, Ilhan</creatorcontrib><creatorcontrib>Yalnızoglu, Dilek</creatorcontrib><creatorcontrib>Uckan, Duygu</creatorcontrib><title>Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab</title><title>Pediatric blood & cancer</title><addtitle>Pediatr Blood Cancer</addtitle><description>Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2‐year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post‐transplant +22nd month and required respiratory support with mechanical ventilation. She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance. She is currently asymptomatic on the 6th month of follow‐up. Pediatr Blood Cancer 2014;61:928–930. © 2013 Wiley Periodicals, Inc.</description><subject>Antibodies, Monoclonal, Murine-Derived - therapeutic use</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>bone marrow transplantation</subject><subject>Combined Modality Therapy</subject><subject>Cyclosporine - therapeutic use</subject><subject>Female</subject><subject>Graft vs Host Disease - etiology</subject><subject>Graft vs Host Disease - therapy</subject><subject>graft-versus-host disease</subject><subject>Griscelli syndrome</subject><subject>Hearing Loss, Sensorineural - complications</subject><subject>Hearing Loss, Sensorineural - therapy</subject><subject>Hematology</subject><subject>Hematopoietic Stem Cell Transplantation - adverse effects</subject><subject>Humans</subject><subject>Immunosuppressive Agents - therapeutic use</subject><subject>Infant</subject><subject>myasthenia gravis</subject><subject>Myasthenia Gravis - diagnosis</subject><subject>Myasthenia Gravis - etiology</subject><subject>Myasthenia Gravis - therapy</subject><subject>Mycophenolic Acid - analogs & derivatives</subject><subject>Mycophenolic Acid - therapeutic use</subject><subject>Oncology</subject><subject>Pediatrics</subject><subject>Piebaldism - complications</subject><subject>Piebaldism - therapy</subject><subject>Pigmentation Disorders - complications</subject><subject>Pigmentation Disorders - therapy</subject><subject>Plasma Exchange</subject><subject>Remission Induction</subject><subject>Rituximab</subject><subject>Transplantation, Homologous</subject><subject>Treatment Outcome</subject><issn>1545-5009</issn><issn>1545-5017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kc9uEzEQh1cIRP_AgRdAlrjAIa0d27vrI0QQQFUBAerR8trjxGXXXmxvm7xInxeHtDkgcbJH_ubTjH9V9YLgM4Lx_Hzs9NmcNUI8qo4JZ3zGMWkeH-5YHFUnKV0XtMa8fVodzRnFTV3j4-ru-6Q1pGSnHuUIKg_gMwoWJbiBCGjYqpTX4J1Cq6huXEKmPPRhBIOUzRCR6vuwAg9OozUMKocxOMilShkGpKHfiZVPY698VtkFj25dXqNSp0Eh2Oi18itAyhsUXZ42blDds-qJVX2C5_fnafXzw_sfi4-ziy_LT4u3FzNNBRGzRjNhbMOgrqGrW2u5ER0HyjurBTE1YcwaQ63SCtes6QyHDmvNWkFaYRSmp9XrvXeM4fcEKcvBpd3MykOYkiQc11S0VDQFffUPeh2m6Mt0O4rjFgvKCvVmT-kYUopg5RjLQnErCZa7sGQJS_4Nq7Av741TN4A5kA_pFOB8D9y6Hrb_N8mv7xYPytm-w5Xf3xw6VPwl64Y2XF5dLuXV50uy_MZaKegfp3Sxyg</recordid><startdate>201405</startdate><enddate>201405</enddate><creator>Unal, Sule</creator><creator>Sag, Erdal</creator><creator>Kuskonmaz, Baris</creator><creator>Kesici, Selman</creator><creator>Bayrakci, Benan</creator><creator>Ayvaz, Deniz C.</creator><creator>Tezcan, Ilhan</creator><creator>Yalnızoglu, Dilek</creator><creator>Uckan, Duygu</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TK</scope><scope>7TO</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201405</creationdate><title>Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab</title><author>Unal, Sule ; Sag, Erdal ; Kuskonmaz, Baris ; Kesici, Selman ; Bayrakci, Benan ; Ayvaz, Deniz C. ; Tezcan, Ilhan ; Yalnızoglu, Dilek ; Uckan, Duygu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3919-7c49df74e66eb68ff5d9b5e35bfc91d6144fdd3faca0647bd5eb0cc489189da03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Antibodies, Monoclonal, Murine-Derived - therapeutic use</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>bone marrow transplantation</topic><topic>Combined Modality Therapy</topic><topic>Cyclosporine - therapeutic use</topic><topic>Female</topic><topic>Graft vs Host Disease - etiology</topic><topic>Graft vs Host Disease - therapy</topic><topic>graft-versus-host disease</topic><topic>Griscelli syndrome</topic><topic>Hearing Loss, Sensorineural - complications</topic><topic>Hearing Loss, Sensorineural - therapy</topic><topic>Hematology</topic><topic>Hematopoietic Stem Cell Transplantation - adverse effects</topic><topic>Humans</topic><topic>Immunosuppressive Agents - therapeutic use</topic><topic>Infant</topic><topic>myasthenia gravis</topic><topic>Myasthenia Gravis - diagnosis</topic><topic>Myasthenia Gravis - etiology</topic><topic>Myasthenia Gravis - therapy</topic><topic>Mycophenolic Acid - analogs & derivatives</topic><topic>Mycophenolic Acid - therapeutic use</topic><topic>Oncology</topic><topic>Pediatrics</topic><topic>Piebaldism - complications</topic><topic>Piebaldism - therapy</topic><topic>Pigmentation Disorders - complications</topic><topic>Pigmentation Disorders - therapy</topic><topic>Plasma Exchange</topic><topic>Remission Induction</topic><topic>Rituximab</topic><topic>Transplantation, Homologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Unal, Sule</creatorcontrib><creatorcontrib>Sag, Erdal</creatorcontrib><creatorcontrib>Kuskonmaz, Baris</creatorcontrib><creatorcontrib>Kesici, Selman</creatorcontrib><creatorcontrib>Bayrakci, Benan</creatorcontrib><creatorcontrib>Ayvaz, Deniz C.</creatorcontrib><creatorcontrib>Tezcan, Ilhan</creatorcontrib><creatorcontrib>Yalnızoglu, Dilek</creatorcontrib><creatorcontrib>Uckan, Duygu</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatric blood & cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Unal, Sule</au><au>Sag, Erdal</au><au>Kuskonmaz, Baris</au><au>Kesici, Selman</au><au>Bayrakci, Benan</au><au>Ayvaz, Deniz C.</au><au>Tezcan, Ilhan</au><au>Yalnızoglu, Dilek</au><au>Uckan, Duygu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab</atitle><jtitle>Pediatric blood & cancer</jtitle><addtitle>Pediatr Blood Cancer</addtitle><date>2014-05</date><risdate>2014</risdate><volume>61</volume><issue>5</issue><spage>928</spage><epage>930</epage><pages>928-930</pages><issn>1545-5009</issn><eissn>1545-5017</eissn><abstract>Myasthenia gravis is among the rare complications after allogeneic hematopoietic stem cell transplantation and is usually associated with chronic GVHD. Herein, we report a 2‐year and 10 months of age female with Griscelli syndrome, who developed severe myasthenia gravis at post‐transplant +22nd month and required respiratory support with mechanical ventilation. She was unresponsive to cyclosporine A, methylprednisolone, intravenous immunoglobulin, and mycophenolate mofetil and the symptoms could only be controlled after plasma exchange and subsequent use of rituximab, in addition to cyclosporine A and mycophenolate mofetil maintenance. She is currently asymptomatic on the 6th month of follow‐up. Pediatr Blood Cancer 2014;61:928–930. © 2013 Wiley Periodicals, Inc.</abstract><cop>United States</cop><pub>Blackwell Publishing Ltd</pub><pmid>24307660</pmid><doi>10.1002/pbc.24799</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1545-5009 |
| ispartof | Pediatric blood & cancer, 2014-05, Vol.61 (5), p.928-930 |
| issn | 1545-5009 1545-5017 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1506398397 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Antibodies, Monoclonal, Murine-Derived - therapeutic use Antineoplastic Agents - therapeutic use bone marrow transplantation Combined Modality Therapy Cyclosporine - therapeutic use Female Graft vs Host Disease - etiology Graft vs Host Disease - therapy graft-versus-host disease Griscelli syndrome Hearing Loss, Sensorineural - complications Hearing Loss, Sensorineural - therapy Hematology Hematopoietic Stem Cell Transplantation - adverse effects Humans Immunosuppressive Agents - therapeutic use Infant myasthenia gravis Myasthenia Gravis - diagnosis Myasthenia Gravis - etiology Myasthenia Gravis - therapy Mycophenolic Acid - analogs & derivatives Mycophenolic Acid - therapeutic use Oncology Pediatrics Piebaldism - complications Piebaldism - therapy Pigmentation Disorders - complications Pigmentation Disorders - therapy Plasma Exchange Remission Induction Rituximab Transplantation, Homologous Treatment Outcome |
| title | Successful treatment of severe myasthenia gravis developed after allogeneic hematopoietic stem cell transplantation with plasma exchange and rituximab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T16%3A36%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20treatment%20of%20severe%20myasthenia%20gravis%20developed%20after%20allogeneic%20hematopoietic%20stem%20cell%20transplantation%20with%20plasma%20exchange%20and%20rituximab&rft.jtitle=Pediatric%20blood%20&%20cancer&rft.au=Unal,%20Sule&rft.date=2014-05&rft.volume=61&rft.issue=5&rft.spage=928&rft.epage=930&rft.pages=928-930&rft.issn=1545-5009&rft.eissn=1545-5017&rft_id=info:doi/10.1002/pbc.24799&rft_dat=%3Cproquest_cross%3E1506398397%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1505080934&rft_id=info:pmid/24307660&rfr_iscdi=true |